Literature DB >> 7499533

Dopamine transporter immunoreactivity in rat brain.

C Freed1, R Revay, R A Vaughan, E Kriek, S Grant, G R Uhl, M J Kuhar.   

Abstract

The dopamine transporter (DAT) is a primary site for the action of cocaine in inducing euphoria. Its action is necessary for the selectivities of dopaminergic neurotoxins that provide the best current experimental models of Parkinson's disease. In the present report, rat dopamine transporter-like immunoreactivity (iDAT) was assessed by immunohistochemistry using newly developed polyclonal antisera raised against conjugated peptides corresponding to sequences found in the dopamine transporter's carboxy- and amino-termini. Dense iDAT was observed in patterns consistent with neural processes and terminals in the striatum, nucleus accumbens, olfactory tubercle, nigrostriatal bundle, and lateral habenula. Perikarya in the substantia nigra pars compacta were immunostained with moderate intensity using one of two immunohistochemical methods, while scattered ventral tegmental area perikarya were stained with somewhat less intensity. Immunoreactive neuronal processes with axonal and dendritic morphologies were stained in the substantia nigra and the paranigral and parabrachialis pigmentosus nuclei of the ventral tegmental area, while sparser processes were noted more medially in the ventral tegmental area. Neuronal processes were found in several laminae in the cingulate cortex, with notable fiber densities in the superficial aspects of lamina I and laminae II/III. The intensities of immunoreactivities in striatum and cerebral cortex were dramatically attenuated ipsilateral to nigrostriatal bundle 6-hydroxydopamine lesions. Specificity of immunostaining was supported by agreement of the results using sera directed against two distinct DAT segments, studies with preimmune and preadsorbed sera and studies of the extracted protein. These antisera identify and reveal details of the distribution of DAT immunoreactivity in rat brain and display variations in levels of DAT expression of likely functional significance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499533     DOI: 10.1002/cne.903590211

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  50 in total

1.  Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum.

Authors:  S J Cragg; S A Greenfield
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens.

Authors:  M J Nirenberg; J Chan; A Pohorille; R A Vaughan; G R Uhl; M J Kuhar; V M Pickel
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

3.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

4.  Alterations in postnatal neurogenesis and dopamine dysregulation in schizophrenia: a hypothesis.

Authors:  Dragos Inta; Andreas Meyer-Lindenberg; Peter Gass
Journal:  Schizophr Bull       Date:  2010-11-19       Impact factor: 9.306

5.  Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area.

Authors:  M J Nirenberg; J Chan; R A Vaughan; G R Uhl; M J Kuhar; V M Pickel
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

6.  Cadherin 13: human cis-regulation and selectively-altered addiction phenotypes and cerebral cortical dopamine in knockout mice.

Authors:  Jana Drgonova; Donna Walther; G Luke Hartstein; Mohammad O Bukhari; Michael H Baumann; Jonathan Katz; Frank Scott Hall; Elizabeth R Arnold; Shaun Flax; Anthony Riley; Olga Rivero-Martin; Klaus-Peter Lesch; Juan Troncoso; Barbara Ranscht; George R Uhl
Journal:  Mol Med       Date:  2016-08-18       Impact factor: 6.354

7.  The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter.

Authors:  Ana M Carneiro; Susan L Ingram; Jean-Martin Beaulieu; Ava Sweeney; Susan G Amara; Sheila M Thomas; Marc G Caron; Gonzalo E Torres
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

8.  Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.

Authors:  Gregory C Hadlock; Anthony J Baucum; Jill L King; Kristen A Horner; Glen A Cook; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

9.  Hyperdopaminergic tone erodes prefrontal long-term potential via a D2 receptor-operated protein phosphatase gate.

Authors:  Tai-Xiang Xu; Tatyana D Sotnikova; Chengyu Liang; Jingping Zhang; Jae U Jung; Roger D Spealman; Raul R Gainetdinov; Wei-Dong Yao
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

10.  Chemical gradients within brain extracellular space measured using low flow push-pull perfusion sampling in vivo.

Authors:  Thomas R Slaney; Omar S Mabrouk; Kirsten A Porter-Stransky; Brandon J Aragona; Robert T Kennedy
Journal:  ACS Chem Neurosci       Date:  2012-11-16       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.